Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

⁃ 1\. Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries.

⁃ Minor injuries are defined as presence of any of the following:

• Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound.

• mild lung contusion detected in the chest CT scan.

• hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress.

• simple limb fractures.

Locations
Other Locations
Egypt
Zagazig University Hospitals
NOT_YET_RECRUITING
Zagazig
Zagazig University Hospitals, Zagazig,
RECRUITING
Zagazig
Contact Information
Primary
Aya Osama Nagaty
doctoraya_15@yahoo.com
00201097721011
Time Frame
Start Date: 2025-01-20
Estimated Completion Date: 2025-06
Participants
Target number of participants: 100
Treatments
Placebo_comparator: Control Arm
Active_comparator: propranolol
propranolol
Active_comparator: carvedilol
Carvid (carvedilol)
Related Therapeutic Areas
Sponsors
Leads: Mansoura University

This content was sourced from clinicaltrials.gov